ZURICH/BERLIN, Sept 4 (Reuters) - The Swiss blue-chip SMI was seen opening 0.4 percent higher at 9,895 points on Wednesday, according to premarket indications by bank Julius Baer.
Here are some of the main factors that may affect Swiss stocks:
Novartis’ gene therapy for blindness, Luxturna, is recommended for use on England’s public health service, the country’s healthcare cost-effectiveness watchdog said.
Sunrise Communications said it had received a new fairness opinion supporting the valuation of Liberty Global’s Swiss UPC business that Sunrise wants to acquire, as it seeks to secure shareholder support for the deal.
The food group is seeing “fantastic growth” for its Nespresso portioned coffee brand in the United States that could become the brand’s biggest market next year, Chief Financial Officer Francois-Xavier Roger told investors.
* Orior said it had increased its stake in Casualfood to 70 %.
* Wisekey International reported an H1 net income of $21.8 million, mainly due to a gain generated from the sale of its SSL/TLS PKI business.
* Roche said datga for its Ocrevus MS drug showed a reduction of disability progression.
* Stadler Rail said it had won a tender for up to 50 trams from Bernmobil.
* Aevis Victoria reported a H1 net profit of 202.1 million Swiss francs.
* Polyphor cut its full year operating cost guidance and reported a first half loss of 27.9 million Swiss francs.
BASLER - Jefferies initiates with “buy” rating
No major Swiss economic data scheduled (Reporting by Zurich newsroom and Berlin Speed Desk)